Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · Real-Time Price · USD
6.79
+0.68 (11.13%)
At close: Dec 5, 2025, 4:00 PM EST
6.81
+0.02 (0.29%)
After-hours: Dec 5, 2025, 7:44 PM EST
Enveric Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 6.13 | 6.45 | 8.85 | 11.73 | 19.88 | 5.32 | |
| Research & Development | 3.38 | 2.84 | 7.25 | 7.91 | 4.76 | 0.17 | |
| Operating Expenses | 9.75 | 9.63 | 16.45 | 19.96 | 25.29 | 5.62 | |
| Operating Income | -9.75 | -9.63 | -16.45 | -19.96 | -25.29 | -5.62 | |
| Interest Expense | -0 | - | - | -0.01 | -0.01 | -0.45 | |
| Interest & Investment Income | - | 0 | 0 | - | - | - | |
| Other Non Operating Income (Expenses) | 0.03 | 0.07 | -0.82 | 7.46 | 8.2 | -0.8 | |
| EBT Excluding Unusual Items | -9.73 | -9.57 | -17.26 | -12.5 | -17.1 | -6.86 | |
| Merger & Restructuring Charges | - | - | - | - | -0.65 | - | |
| Impairment of Goodwill | - | - | - | -1.49 | -8.23 | - | |
| Asset Writedown | - | - | - | -5.97 | -30.45 | - | |
| Pretax Income | -9.73 | -9.57 | -17.26 | -19.96 | -56.43 | -6.86 | |
| Income Tax Expense | 0.01 | 0.01 | 0.03 | -1.49 | -7.45 | - | |
| Net Income | -9.73 | -9.57 | -17.29 | -18.47 | -48.98 | -6.86 | |
| Preferred Dividends & Other Adjustments | 1.51 | - | 0.17 | 0.33 | - | - | |
| Net Income to Common | -11.25 | -9.57 | -17.46 | -18.8 | -48.98 | -6.86 | |
| Shares Outstanding (Basic) | 0 | 0 | 0 | - | - | - | |
| Shares Outstanding (Diluted) | 0 | 0 | 0 | - | - | - | |
| Shares Change (YoY) | 484.62% | 249.38% | - | - | - | - | |
| EPS (Basic) | -61.29 | -228.48 | -1455.50 | - | - | - | |
| EPS (Diluted) | -61.29 | -228.48 | -1455.50 | - | - | - | |
| Free Cash Flow | -7.67 | -7.73 | -14.1 | -17.73 | -11.65 | -3.89 | |
| Free Cash Flow Per Share | -41.79 | -184.36 | -1175.46 | - | - | - | |
| EBITDA | -9.51 | -9.29 | -16.1 | -19.63 | -24.64 | -5.5 | |
| D&A For EBITDA | 0.24 | 0.34 | 0.34 | 0.33 | 0.66 | 0.12 | |
| EBIT | -9.75 | -9.63 | -16.45 | -19.96 | -25.29 | -5.62 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.